Cornerstone Advisory LLP raised its position in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,489 shares of the medical research company’s stock after buying an additional 3 shares during the period. Cornerstone Advisory LLP’s holdings in Amgen were worth $531,000 as of its most recent filing with the SEC.
Other large investors have also bought and sold shares of the company. Oak Associates Ltd. OH increased its position in Amgen by 0.3% in the first quarter. Oak Associates Ltd. OH now owns 210,710 shares of the medical research company’s stock worth $31,592,000 after buying an additional 581 shares during the last quarter. National Pension Service increased its position in Amgen by 4.2% in the first quarter. National Pension Service now owns 378,322 shares of the medical research company’s stock worth $56,722,000 after buying an additional 15,376 shares during the last quarter. Geode Capital Management LLC increased its position in Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock worth $964,334,000 after buying an additional 132,632 shares during the last quarter. Prudential PLC increased its position in Amgen by 41.4% in the first quarter. Prudential PLC now owns 1,062,893 shares of the medical research company’s stock worth $159,359,000 after buying an additional 311,157 shares during the last quarter. Finally, Legal & General Group Plc increased its position in Amgen by 1.0% in the first quarter. Legal & General Group Plc now owns 3,263,086 shares of the medical research company’s stock worth $489,239,000 after buying an additional 32,086 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ:AMGN) opened at 166.81 on Monday. The firm’s 50 day moving average is $171.68 and its 200 day moving average is $161.02. The stock has a market capitalization of $124.83 billion, a P/E ratio of 17.07 and a beta of 0.94. Amgen Inc. has a 1-year low of $138.06 and a 1-year high of $176.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.57 EPS. On average, equities research analysts anticipate that Amgen Inc. will post $11.36 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were issued a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.40%. Amgen’s dividend payout ratio (DPR) is 40.90%.
A number of research analysts recently issued reports on AMGN shares. Jefferies Group reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, September 28th. Vetr upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $188.11 target price on the stock in a research report on Thursday. Robert W. Baird reiterated an “outperform” rating and set a $157.00 target price on shares of Amgen in a research report on Friday, August 26th. Gabelli began coverage on shares of Amgen in a research report on Friday, August 26th. They set a “hold” rating on the stock. Finally, BMO Capital Markets restated an “outperform” rating and set a $190.00 price objective on shares of Amgen in a report on Thursday, September 22nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Amgen presently has an average rating of “Buy” and an average target price of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.